Xilio Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
11. Net Loss Per Share
The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding. The weighted average number of shares of common stock used in the basic and diluted net loss per share calculation includes prefunded warrants to purchase common stock that were outstanding during the years ended December 31, 2025 and 2024, as the prefunded warrants are exercisable at any time for nominal cash consideration. As of December 31, 2025,524,033 prefunded warrants have been exercised and 8,502,224 prefunded warrants are outstanding.
The following table sets forth the outstanding shares of common stock equivalents, presented based on amounts outstanding at each period end, that were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2025 | 2024 | |
| Unvested restricted stock units | 23,866 | 31,818 |
| Outstanding stock options | 2,785,102 | 595,074 |
| Common stock warrants | 8,206,109 | 188 |
| Unvested employee stock purchase plan shares | 4,983 | 3,338 |
| Total common stock equivalents | 11,020,060 | 630,418 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.